Blue Owl Capital Holdings LP Has $18.62 Million Stock Position in Compass Therapeutics, Inc. $CMPX

Blue Owl Capital Holdings LP lifted its holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX) by 33.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,466,525 shares of the company’s stock after acquiring an additional 875,000 shares during the period. Compass Therapeutics accounts for approximately 1.4% of Blue Owl Capital Holdings LP’s holdings, making the stock its 7th biggest holding. Blue Owl Capital Holdings LP’s holdings in Compass Therapeutics were worth $18,615,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in CMPX. Suvretta Capital Management LLC raised its position in Compass Therapeutics by 97.2% in the 3rd quarter. Suvretta Capital Management LLC now owns 14,101,159 shares of the company’s stock worth $49,354,000 after purchasing an additional 6,951,666 shares during the period. Vivo Capital LLC raised its position in Compass Therapeutics by 57.9% in the 3rd quarter. Vivo Capital LLC now owns 9,545,466 shares of the company’s stock worth $33,409,000 after purchasing an additional 3,502,000 shares during the period. Balyasny Asset Management L.P. purchased a new stake in Compass Therapeutics in the 3rd quarter worth about $9,892,000. Millennium Management LLC raised its position in Compass Therapeutics by 280.4% in the 3rd quarter. Millennium Management LLC now owns 3,237,572 shares of the company’s stock worth $11,332,000 after purchasing an additional 2,386,367 shares during the period. Finally, Vanguard Group Inc. raised its position in Compass Therapeutics by 45.6% in the 3rd quarter. Vanguard Group Inc. now owns 7,062,799 shares of the company’s stock worth $24,720,000 after purchasing an additional 2,212,794 shares during the period. 68.43% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Compass Therapeutics in a research report on Thursday, March 12th. Jefferies Financial Group reissued a “buy” rating and issued a $9.00 price objective on shares of Compass Therapeutics in a research report on Thursday, March 5th. Raymond James Financial lowered shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, April 28th. Craig Hallum assumed coverage on shares of Compass Therapeutics in a research report on Friday, February 13th. They issued a “buy” rating and a $15.00 price objective on the stock. Finally, Wall Street Zen lowered shares of Compass Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 25th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Compass Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $13.60.

Compass Therapeutics Stock Performance

Shares of NASDAQ:CMPX opened at $2.07 on Monday. The firm has a market cap of $372.79 million, a PE ratio of -5.05 and a beta of 0.79. The firm’s 50 day simple moving average is $4.12 and its 200-day simple moving average is $5.01. Compass Therapeutics, Inc. has a one year low of $1.61 and a one year high of $6.88.

Compass Therapeutics (NASDAQ:CMPX) last issued its earnings results on Tuesday, May 5th. The company reported ($0.10) EPS for the quarter, hitting analysts’ consensus estimates of ($0.10). Equities research analysts predict that Compass Therapeutics, Inc. will post -0.44 EPS for the current fiscal year.

Compass Therapeutics Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.